These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 18473295

  • 1. [spACE, the last frontier? Renin inhibition in hypertension].
    Villa L.
    G Ital Nefrol; 2008; 25(3):274. PubMed ID: 18473295
    [No Abstract] [Full Text] [Related]

  • 2. Aliskiren/valsartan (Valturna) for hypertension.
    Med Lett Drugs Ther; 2009 Nov 30; 51(1326):94-5. PubMed ID: 20224524
    [No Abstract] [Full Text] [Related]

  • 3. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, Stanton A.
    Hypertension; 2007 Feb 30; 49(2):276-84. PubMed ID: 17159081
    [Abstract] [Full Text] [Related]

  • 4. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.
    Curr Med Res Opin; 2008 Apr 30; 24(4):1039-47. PubMed ID: 18307835
    [Abstract] [Full Text] [Related]

  • 5. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
    Middeke M.
    Dtsch Med Wochenschr; 2012 Nov 30; 137(48):2498. PubMed ID: 23168983
    [No Abstract] [Full Text] [Related]

  • 6. Aliskiren and valsartan combination therapy for the management of hypertension.
    Epstein BJ.
    Vasc Health Risk Manag; 2010 Sep 07; 6():711-22. PubMed ID: 20859542
    [Abstract] [Full Text] [Related]

  • 7. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
    Moniwa N, Varagic J, Ahmad S, VonCannon JL, Simington SW, Wang H, Groban L, Brosnihan KB, Nagata S, Kato J, Kitamura K, Gomez RA, Lopez ML, Ferrario CM.
    Hypertension; 2013 Feb 07; 61(2):417-24. PubMed ID: 23232645
    [Abstract] [Full Text] [Related]

  • 8. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
    Chrysant SG.
    Drugs Today (Barc); 2010 Mar 07; 46(3):151-62. PubMed ID: 20467589
    [Abstract] [Full Text] [Related]

  • 9. Renin inhibition: the holy grail of renin-angiotensin system blockade?
    McInnes GT.
    J Hum Hypertens; 2007 Oct 07; 21(10):766-9. PubMed ID: 17541389
    [No Abstract] [Full Text] [Related]

  • 10. Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases.
    Yarows SA.
    Expert Rev Cardiovasc Ther; 2010 Jan 07; 8(1):19-33. PubMed ID: 20030022
    [Abstract] [Full Text] [Related]

  • 11. [Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data].
    Paoletti V, Di Veroli C, Pugliese M, Cammarella I, Cavina G, Turchetti P, Mammarella A.
    Clin Ter; 2002 Jan 07; 153(1):61-4. PubMed ID: 11963637
    [Abstract] [Full Text] [Related]

  • 12. Comparative role of angiotensin receptor blockers versus other agents in the management of hypertension, cardiovascular disease and nephropathy.
    Tempelhof MW.
    South Med J; 2009 Dec 07; 102(12):1201-2. PubMed ID: 20016423
    [No Abstract] [Full Text] [Related]

  • 13. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V, Buksa M, Loza V, Kulic M.
    Med Arh; 2009 Dec 07; 63(6):343-9. PubMed ID: 20380117
    [Abstract] [Full Text] [Related]

  • 14. [Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
    Coca A, Giner V.
    Rev Esp Cardiol; 1999 Dec 07; 52 Suppl 3():53-8. PubMed ID: 10614150
    [Abstract] [Full Text] [Related]

  • 15. Renin-angiotensin system blocking drugs.
    Robles NR, Cerezo I, Hernandez-Gallego R.
    J Cardiovasc Pharmacol Ther; 2014 Jan 07; 19(1):14-33. PubMed ID: 24038019
    [Abstract] [Full Text] [Related]

  • 16. Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.
    Freiberger V, Amann K, Heemann U, Frank H.
    Transpl Int; 2009 Nov 07; 22(11):1110-3. PubMed ID: 19497068
    [Abstract] [Full Text] [Related]

  • 17. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
    Sepehrdad R, Frishman WH, Stier CT, Sica DA.
    Cardiol Rev; 2007 Nov 07; 15(5):242-56. PubMed ID: 17700383
    [Abstract] [Full Text] [Related]

  • 18. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
    Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM.
    Clin Sci (Lond); 2012 Dec 07; 123(11):649-58. PubMed ID: 22715807
    [Abstract] [Full Text] [Related]

  • 19. Aliskiren combined with losartan in diabetes and nephropathy.
    Lindner T.
    N Engl J Med; 2008 Sep 04; 359(10):1068-9; author reply 1069-70. PubMed ID: 18777612
    [No Abstract] [Full Text] [Related]

  • 20. Aliskiren and dual therapy in type 2 diabetes mellitus.
    Ingelfinger JR.
    N Engl J Med; 2008 Jun 05; 358(23):2503-5. PubMed ID: 18525047
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.